Sarcopenia Treatment Market by Treatment (Protein Supplements, Vitamin B12 Supplements, Vitamin D & Calcium Supplements and Others), Route of Administration (Oral, Parenteral, and Enteral), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies: Global Opportunity Analysis and Industry Forecast, 2021-2030
- ALL4676931
- 239 Pages
- September 2021
- Diagnostic and Biotech
Sarcopenia is a type of muscle loss (muscle atrophy) that occurs with aging and immobility. It is characterized by the degenerative loss of skeletal muscle mass, quality, and strength. The rate of muscle loss is dependent on exercise level, co-morbidities, nutrition and other factors. The muscle loss is related to changes in muscle synthesis signaling pathways. Sarcopenia is caused by an imbalance between signals for muscle cell growth and signals for teardown. Cell growth processes are called “anabolism,” and cell teardown processes are called “catabolism.
The global sarcopenia treatment market is anticipated to witness growth substantially during the forecast period, owing to rise in geriatric population and their adoption of vitamins and dietary supplements for improved treatment of this illness. Furthermore, rise in investments in production of drugs and supplements for the treatment of sarcopenia are expected to boost growth of the sarcopenia treatment market. Furthermore, a growing number of pharmaceutical and food processing companies are focused on developing nutrition supplements for treatment of sarcopenia. In addition, rise in malnutrition and Vitamin Deficiency in developing countries is one of the major driving factors of this market. Hence, these factors further augment the global sarcopenia treatment market.
Over the years, the global sarcopenia treatment market has witnessed huge growth due to the advancements in diagnostics, treatment, and drug discovery techniques. Moreover, increase in demand for effective sarcopenia treatment and therapeutic options encourages major pharmaceutical companies to invest in R&D, thus creating future growth opportunities. However, high-cost of protein supplements and lack of awareness are expected to hamper the market growth in upcoming years.
The global sarcopenia treatment market is classified on the basis of treatment, by route of administration, by distribution channel, and region. By treatment, the market is divided into vitamin B12 supplement, Vitamin D & Calcium supplement, protein supplements and others. By route of administration, the market is segmented into oral, parenteral, and enteral. The oral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. The parenteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The enteral segment is further segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By distribution channel, it is categorized hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the market is analyzed across, North America, Europe, Asia-Pacific and LAMEA.
The report provides extensive competitive analysis and profiles of key market players, such as Abbott laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc., Nestle S.A., Pfizer, Inc. Novartis AG, Sanofi Inc., Zydus Cadila, Ltd. and F-Hoffmann La-Roche.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of four regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Treatment
• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements
• Others
By Route of Administration
• Oral
o Hospital Pharmacies
o Drug Stores & Retail Pharmacies
o Online Pharmacies
• Parenteral
o Hospital Pharmacies
o Drug Stores & Retail Pharmacies
o Online Pharmacies
• Enteral
o Hospital Pharmacies
o Drug Stores & Retail Pharmacies
o Online Pharmacies
By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Saudi Arabia
o Rest of LAMEA
KEY MARKET PLAYERS
• Abbott laboratories, Inc.
• American Way (Amway) Corporation
• Bayer AG
• GlaxoSmithKline plc
• Nestle S.A.
• Pfizer, Inc.
• Novartis AG
• Sanofi, Inc.
• Zydus Cadila, Ltd
• F-Hoffmann La-Roche
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Becton and Dickinson company
• Thermo fisher scientific Inc.
• Medtronic Plc.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top players positioning, 2020
3.3.Porter’s five force analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in geriatric Population
3.4.1.2.Increase in initiatives by government and private organizations for sarcopenia treatment
3.4.2.Restraint
3.4.2.1.Lack of effective therapies for sarcopenia
3.4.3.Opportunities
3.4.3.1.Increase in the adoption of supplements
3.4.3.2.Increase in malnutrition and Vitamin Deficiency in developing countries
3.4.4.Impact analysis
3.5.COVID-19 impact on the global sarcopenia treatment market
CHAPTER 4:SARCOPENIA TREATMENT MARKET, BY TREATMENT
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Protein supplements
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Vitamin B-12 supplements
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Vitamin D & calcium supplements
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1.Overview
5.1.1.Market size and forecast, by route of administration
5.2.Oral
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by distribution channel
5.3.Parenteral
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by distribution channel
5.4.Enteral
5.4.1.Market size and forecast by region
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by distribution channel
CHAPTER 6:SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast, by distribution channel
6.2.Hospital- pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug stores & retail pharmacy
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online Pharmacy
6.4.1.Market size and forecast , by region
6.4.2.Market analysis, by country
CHAPTER 7:SARCOPENIA TREATMENT MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast, by region
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. sarcopenia treatment market, by treatment
7.2.2.1.2.U.S sarcopenia treatment market, by route of administration
7.2.2.1.3.U.S. sarcopenia treatment market, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Canada sarcopenia treatment market, by disease
7.2.2.2.2.Canada sarcopenia treatment market, by route of administration
7.2.2.2.3.Canada sarcopenia treatment market, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Mexico sarcopenia treatment market, by treatment
7.2.2.3.2.Mexico sarcopenia treatment market, by route of administration
7.2.2.3.3.Mexico sarcopenia treatment market by distribution channel
7.2.3.North America market size and forecast, by treatment
7.2.4.North America market size and forecast, by route of administration
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany sarcopenia treatment market, by disease
7.3.2.1.2.Germany sarcopenia treatment market, by route of administration
7.3.2.1.3.Germany sarcopenia treatment market, by distribution channel
7.3.2.2.France
7.3.2.2.1.France sarcopenia treatment market, by treatment
7.3.2.2.2.France sarcopenia treatment market, by route of administration
7.3.2.2.3.France sarcopenia treatment market, by distribution channel
7.3.2.3.UK
7.3.2.3.1.UK sarcopenia treatment market, by treatment
7.3.2.3.2.UK sarcopenia treatment market, by route of administration
7.3.2.3.3.UK sarcopenia treatment market, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Italy sarcopenia treatment market, by treatment
7.3.2.4.2.Italy sarcopenia treatment market, by route of administration
7.3.2.4.3.Italy sarcopenia treatment market, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Spain sarcopenia treatment market, by treatment
7.3.2.5.2.Spain sarcopenia treatment market, by route of administration
7.3.2.5.3.Spain sarcopenia treatment market, by distribution channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe sarcopenia treatment market, by treatment
7.3.2.6.2.Rest of Europe sarcopenia treatment market, by route of administration
7.3.2.6.3.Rest of Europe sarcopenia treatment market, by distribution channel
7.3.3.Europe market size and forecast, by treatment
7.3.4.Europe market size and forecast, by route of administration
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan sarcopenia treatment market, by treatment
7.4.2.1.2.Japan sarcopenia treatment market, by route of administration
7.4.2.1.3.Japan sarcopenia treatment market, by distribution channel
7.4.2.2.China
7.4.2.2.1.China sarcopenia treatment market, by treatment
7.4.2.2.2.China sarcopenia treatment market, by route of administration
7.4.2.2.3.China sarcopenia treatment market, by distribution channel
7.4.2.3.Australia
7.4.2.3.1.Australia sarcopenia treatment market, by treatment
7.4.2.3.2.Australia sarcopenia treatment market, by route of administration
7.4.2.3.3.Australia sarcopenia treatment market, by distribution channel
7.4.2.4.India
7.4.2.4.1.India sarcopenia treatment market, by treatment
7.4.2.4.2.India sarcopenia treatment market, by route of administration
7.4.2.4.3.India sarcopenia treatment market, by distribution channel
7.4.2.5.South Korea
7.4.2.5.1.South Korea sarcopenia treatment market, by treatment
7.4.2.5.2.South Korea sarcopenia treatment market, by route of administration
7.4.2.5.3.South Korea sarcopenia treatment market, by distribution channel
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific sarcopenia treatment market, by treatment
7.4.2.6.2.Rest of Asia-Pacific sarcopenia treatment market, by route of administration
7.4.2.6.3.Rest of Asia-Pacific sarcopenia treatment market, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by treatment
7.4.4.Asia-Pacific market size and forecast, by route of administration
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil sarcopenia treatment market, by treatment
7.5.2.1.2.Brazil sarcopenia treatment market, by route of administration
7.5.2.1.3.Brazil sarcopenia treatment market, by distribution channel
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia sarcopenia treatment market, by treatment
7.5.2.2.2.Saudi Arabia sarcopenia treatment market, by route of administration
7.5.2.2.3.Saudi Arabia sarcopenia treatment market, by distribution channel
7.5.2.3.South Africa
7.5.2.3.1.South Africa sarcopenia treatment market, by treatment
7.5.2.3.2.South Africa sarcopenia treatment market, by route of administration
7.5.2.3.3.South Africa sarcopenia treatment market, by distribution channel
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA sarcopenia treatment market, by treatment
7.5.2.4.2.Rest of LAMEA sarcopenia treatment market, by route of administration
7.5.2.4.3.Rest of LAMEA sarcopenia treatment market, by distribution channel
7.5.3.LAMEA market size and forecast, by treatment
7.5.4.LAMEA market size and forecast, by route of administration
7.5.5.LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES, INC
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.American Way (Amway)Corporation
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.3.Bayer AG
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.F. HOFFMANN-LA ROCHE LTD.
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.GlaxoSmithKline plc
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.NESTLÉ S.A.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Novartis AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Business performance
8.8.PFIZER INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.SANOFI INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Zydus Cadilla, Ltd
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.1.Business performance
TABLE 01.GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 02.SARCOPENIA TREATMENT MARKET FOR PROTIENS SUPPLEMENTS, BY REGION, 2020–2030 ($MILLION)
TABLE 03.SARCOPENIA TREATMENT MARKET FOR VITAMIN B12 SUPPLEMENT, BY REGION, 2020–2030 ($MILLION)
TABLE 04.SARCOPENIA TREATMENT MARKET FOR VITAMIN D & CALCIUM SUPPLEMENTS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.SARCOPENIA TREATMENT MARKETFOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 07.SARCOPENIA TREATMENT MARKET FOR ORAL, BY REGION, 2020–2030 ($MILLION)
TABLE 08.SARCOPENIA TREATMENT MARKET FOR ORAL, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 09.SARCOPENIA TREATMENT MARKETFOR PARENTERAL ADMINISTRATION, BY REGION, 2020–2030 ($MILLION)
TABLE 10.PARENTERAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 11.SARCOPENIA TREATMENT MARKETFOR ENTERAL, BY REGION, 2020–2030 ($MILLION)
TABLE 12.SARCOPENIA TREATMENT MARKET FOR ENTERAL, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 13.GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 14.HOSPITAL-BASED PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 15.SARCOPENIA TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 16.SARCOPENIA TREATMENT MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 17.GLOBAL SARCOPENIA TREATMENT MARKETGLOBAL, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 20.U.S. SARCOPENIA TREATMENT MARKET, BYROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 21.U.S. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 22.. CANADA. SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 23.CANADA SARCOPENIA TREATMENT MARKET, BYROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 24.CANADA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 25.MEXICO SARCOPENIA TREATMENT MARKET, TREATMENT, 2020–2030 ($MILLION)
TABLE 26.MEXICO SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 27.MEXICO SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION, CHANNEL 2020–2030 ($MILLION)
TABLE 31.EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32.GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 33.GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 34.GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 35.FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 36.FRANCE L SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 37.FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 38.UK SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 39.UK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 40.UK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41.ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 42.ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 43.ITALY L SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 44.SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 45.SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 46.SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 50.EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 51.EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 52.EUROPE G SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 55.JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 56.JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 57.CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 58.CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 59.CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 63.INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 64.INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 65.INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 75.LAMEA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76.BRAZIL SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 77.BRAZIL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 78.BRAZIL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 88.LAMEA SARCOPENIA TREATMENT MARKET, BY TREATMENT, 2020–2030 ($MILLION)
TABLE 89.LAMEA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 90.LAMEA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 91.ABBOTT: COMPANY SNAPSHOT
TABLE 92.ABBOTT: OPERATING SEGMENTS
TABLE 93.ABBOTT: PRODUCT PORTFOLIO
TABLE 94.AMWAY: COMPANY SNAPSHOT
TABLE 95.AMWAY: OPERATING BUSINESS SEGMENTS
TABLE 96.AMWAY: PRODUCT PORTFOLIO
TABLE 97.BAYER: COMPANY SNAPSHOT
TABLE 98.BAYER: OPERATING SEGMENTS
TABLE 99.BAYER: PRODUCT PORTFOLIO
TABLE 100.ROCHE: COMPANY SNAPSHOT
TABLE 101.ROCHE: OPERATING SEGMENTS
TABLE 102.ROCHE: PRODUCT PORTFOLIO
TABLE 103.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 104.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 105.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 106.NESTLÉ: COMPANY SNAPSHOT
TABLE 107.NESTLÉ: OPERATING SEGMENTS
TABLE 108.NESTLÉ: PRODUCT PORTFOLIO
TABLE 109.NOVARTIS: COMPANY SNAPSHOT
TABLE 110.NOVARTIS: OPERATING SEGMENTS
TABLE 111.NOVARTIS: PRODUCT PORTFOLIO
TABLE 112.PFIZER: COMPANY SNAPSHOT
TABLE 113.PFIZER: OPERATING SEGMENTS
TABLE 114.PFIZER: PRODUCT PORTFOLIO
TABLE 115.SANOFI: COMPANY SNAPSHOT
TABLE 116.SANOFI: OPERATING SEGMENTS
TABLE 117.SANOFI: PRODUCT PORTFOLIO
TABLE 118.ZYDUS: COMPANY SNAPSHOT
TABLE 119.ZYDUS: OPERATING SEGMENTS
TABLE 120.ZYDUS: PRODUCT PORTFOLIO
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
